PSI™ Enables Cell Engineering and Therapy from Discovery to Predicting Outcome

Learn how PSI helps you discover and reveal the key potent cell subsets that correlate to in vivo outcome in cell therapy throughout discovery and development.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Use Polyfunctionality and PSI to reveal synergies and mechanism with novel Combination Therapies
Use PSI to clearly reveal differences in bioprocessing methods for product manufacturing process optimization
Predict patient response to a CAR-T therapy using pre-infusion product PSI, demonstrating its potential as a biomarker for clinical outcome
A Deeper Look

More about this

Ensuring the Continued Success of Engineered Immune Cell Therapies in the Fight Against Cancer

CAR-T cell-based immunotherapies have had remarkable success in recent years, but challenges remain.

Reengineered T cells are living products whose behavior has been difficult to characterize and predict with existing technologies. Once they are re-infused into the patient, they may result in life-threatening immunotoxicity such as cytokine release syndrome (CRS) and neurologic toxicity.

Download this App Note to learn how IsoPlexis’ Polyfunctional Strength Index (PSI™) can be utilized to address these challenges, in particular, to provide metrics that uniquely relate the cell product response to in vivo preclinical and clinical outcome measures.

awards-bar-3-wide-color-right
awards-bar-4-wide-color-left
Get the